Following promising clinical trials, Dr Sari Prutchi Sagiv outlines the potential of Talent Biotechs’ cannabidiol (CBD) based therapies to transform the lives of bone marrow transplant patients suffering from GvHD.
Talent Biotechs has at long last completed two four-phase clinical trials showing outstanding preliminary results in the prevention and treatment of Graft vs. Host Disease (GvHD) with CBD taken orally. It has also completed two cohorts (of 12 patients each) in an ongoing open-label dose-response clinical study to evaluate the pharmacokinetic profile, safety and efficacy of various doses of CBD for the prevention of acute GvHD, obtaining promising results.
Talent Biotechs, a clinical-stage pharmaceutical company, develops cannabidiol (CBD) to treat serious diseases. Its current focus is on mitigating the incidence and effects of GvHD following bone marrow transplants
Bone marrow transplant boosts survival rates
A major breakthrough in fighting cancer, bone marrow transplant procedures have boosted survival rates in various forms of blood cancers, such as leukaemia, lymphoma or multiple myeloma, from nearly zero to over 85%.
Unfortunately, bone marrow recipients are likely to develop GvHD, a terrible complication that occurs when the transplanted cells from a donor – the graft – deem the transplant recipient – the host – to be foreign. This may occur within just days (acute GvHD) and up to months or even…
Original Author Link click here to read complete story..
